Skip to main content

Yeaman Kevin J's Form 4 filing

Dolby Laboratories, Inc. (DLB) · filed Aug 11, 2021

Accession no.
0001209191-21-050988
Filed
Aug 11, 2021
Trade date
Aug 10, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.84M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yeaman Kevin JCIK 0001200469Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 10, 2021Class A Common StockMOption exerciseAcquired+29,457$37.35+$1,100,218.9562,352Indirect
Aug 10, 2021Class A Common StockSSaleDisposed−19,796$96.03F1−$1,901,009.8842,556Indirect
Aug 10, 2021Class A Common StockSSaleDisposed−9,253$97.18F2−$899,206.5433,303Indirect
Aug 10, 2021Class A Common StockSSaleDisposed−408$97.77−$39,890.1632,895Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 10, 2021Class A Common StockMOption exerciseDisposed−29,457$0.00$044,187Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were sold in multiple transactions at prices ranging from $95.73 to $96.62, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F2

The shares were sold in multiple transactions at prices ranging from $96.77 to $97.679 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Remarks

**All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.**

Read the full filing on SEC EDGAR (opens in a new tab)